To investigate the role of microRNA-106a in reactivating the silenced MECP2 gene on the X chromosome in mouse models of Rett syndrome.
Approach:
CRISPR-Cas9 Screening: The study performed a genome-wide CRISPR-Cas9 screen in female mouse fibroblasts to identify microRNAs involved in maintaining X chromosome inactivation.
Gene Therapy: Researchers delivered an adeno-associated virus (AAV9) carrying a miR106a-targeting 'sponge' into the brains of female mice with heterozygous Mecp2 mutations.
Key Findings:
Inhibition of miR106a restored MECP2 expression to about 32% of normal levels.
Treated mice showed significant improvements in locomotion, exploratory behavior, and brain volume.
Median survival of treated mice was 29.6 weeks compared to 12.1 weeks for controls.
Interpretation:
Limitations:
The study was conducted in mouse models, and results may not directly translate to humans.
Further research is needed to assess long-term effects and safety of the treatment.
Federal prosecutors allege that a Florida physician and research staff fabricated clinical trial records that were submitted into database systems used to evaluate investigational drugs.
